Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist.
The melanocortin-4 receptor (MC4R) is a G-protein-coupled receptor (GPCR) that is expressed in the central nervous system and has a role in regulating feeding behavior, obesity, energy homeostasis, male erectile response, and blood pressure. Since the report of the MC4R knockout mouse in 1997, the field has been searching for links between this genetic biomarker and human obesity and type 2 diabetes. More then 80 single nucleotide polymorphisms (SNPs) have been identified from human patients, both obese and nonobese controls. Many significant studies have been performed examining the pharmacological characteristics of these hMC4R SNPs in attempts to identify a molecular defects/insights that might link a genetic factor to the obese phenotype observed in patients possessing these mutations. Our laboratory has previously reported the pharmacological characterization of 40 of these polymorphic hMC4 receptors with multiple endogenous and synthetic ligands. The goal of the current study is to perform a similar comprehensive side-by-side characterization of 30 additional human hMC4R with single nucleotide polymorphisms using multiple endogenous agonists [alpha-, beta-, and gamma(2)-melanocyte stimulating hormones (MSH) and adrenocorticotropin (ACTH)], the antagonist agouti-related protein hAGRP(87-132), and synthetic agonists [NDP-MSH, MTII, and the tetrapeptide Ac-His-dPhe-Arg-Trp-NH(2) (JRH887-9)]. These in vitro data, in some cases, provide a putative molecular link between dysfunctional hMC4R's and human obesity. These 30 hMC4R SNPs include R7H, R18H, R18L, S36Y, P48S, V50M, F51L, E61K, I69T, D90N, S94R, G98R, I121T, A154D, Y157S, W174C, G181D, F202L, A219 V, I226T, G231S, G238D, N240S, C271R, S295P, P299L, E308K, I317V, L325F, and 750DelGA. All but the N240S hMC4R were identified in obese patients. Additionally, we have characterized a double I102T/V103I hMC4R. In addition to the pharmacological characterization, the hMC4R variants were evaluated for cell surface expression by flow cytometry. The F51L, I69T, and A219V hMC4Rs possessed full agonist activity and significantly decreased endogenous agonist ligand potency. At the E61K, D90N, Y157S, and C271R hMC4Rs, all agonist ligands examined were only partially efficacious in generating a maximal signaling response (partial agonists) and possessed significantly decreased endogenous agonist ligand potency. Only the A219V, G238D, and S295P hMC4Rs possessed significantly decreased AGRP(87-132) antagonist potency. These data provide new information for use in GPCR computational development as well as insights into MC4R structure ad function.
Xiang
Zhimin
Z
Department of Pharmacodynamics, University of Florida, Gainesville, Florida 32610, USA.
Proneth
Bettina
B
Dirain
Marvin L
ML
Litherland
Sally A
SA
Haskell-Luevano
Carrie
C
D054369:Agouti-Related Protein / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology*; D000595:Amino Acid Sequence; D001667:Binding, Competitive / Q000187:drug effects / Q000235:genetics; D002460:Cell Line; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D008024:Ligands; D008297:Male; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D009765:Obesity / Q000235:genetics / Q000378:metabolism; D011110:Polymorphism, Genetic; D011333:Pro-Opiomelanocortin / Q000819:agonists / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000502:physiology*; D011485:Protein Binding / Q000187:drug effects / Q000235:genetics; D044105:Receptor, Melanocortin, Type 4 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics*; D000521:alpha-MSH / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology; D019824:beta-MSH / Q000378:metabolism / Q000494:pharmacology; D019825:gamma-MSH / Q000378:metabolism / Q000494:pharmacology
D054369:Agouti-Related Protein; D008024:Ligands; C470072:MC4R protein, human; D044105:Receptor, Melanocortin, Type 4; D019824:beta-MSH; D019825:gamma-MSH; D000521:alpha-MSH; D011333:Pro-Opiomelanocortin; C027756:MSH, 4-Nle-7-Phe-alpha-
Cell. 1997 Jan 10;88(1):131-41
9019399
Cell. 1992 Dec 24;71(7):1195-204
1473152
Nature. 1969 Feb 15;221(5181):667-9
4304587
Science. 1997 Oct 3;278(5335):135-8
9311920
Trends Pharmacol Sci. 1995 Dec;16(12):413-7
8578614
J Med Chem. 2005 Apr 21;48(8):3060-75
15828845
Eur J Pharmacol. 2003 Feb 21;462(1-3):41-52
12591094
Diabetes. 2003 Dec;52(12):2996-3000
14633862
Proc Natl Acad Sci U S A. 1980 Oct;77(10):5754-8
6777774
J Pediatr. 2001 Aug;139(2):204-9
11487744
J Med Chem. 1989 Dec;32(12):2555-61
2555512
Clin Endocrinol (Oxf). 2008 Apr;68(4):529-35
17941900
Arch Int Pharmacodyn Ther. 1974 Mar;208(1):19-23
4367710
J Clin Endocrinol Metab. 2004 Feb;89(2):904-8
14764812
J Clin Endocrinol Metab. 2004 Feb;89(2):940-5
14764818
J Biol Chem. 1980 Aug 10;255(15):7108-17
6248546
J Med Chem. 2001 Jun 21;44(13):2247-52
11405661
J Clin Endocrinol Metab. 2005 Oct;90(10):5632-8
16030156
Mol Endocrinol. 1994 Oct;8(10):1298-308
7854347
Endocrinology. 2009 Jan;150(1):114-25
18801902
Nature. 2007 Nov 15;450(7168):383-7
17952055
Science. 1992 Aug 28;257(5074):1248-51
1325670
Biotechniques. 1988 Jul-Aug;6(7):632-8
3273409
Biochemistry. 2001 May 22;40(20):6164-79
11352754
Biochemistry. 2007 Jul 17;46(28):8273-87
17590021
J Biol Chem. 2003 Jun 20;278(25):22939-45
12690102
Peptides. 2003 Jan;24(1):73-82
12576087
N Engl J Med. 2003 Mar 20;348(12):1085-95
12646665
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):15043-8
9844012
Endocr Rev. 1988 Feb;9(1):159-79
3286233
Regul Pept. 2001 May 5;99(1):1-7
11257308
J Biol Chem. 2002 Dec 6;277(49):47662-70
12244039
Hum Mol Genet. 2003 Jan 15;12(2):145-53
12499395
Nature. 1997 Jan 9;385(6612):165-8
8990120
Ann N Y Acad Sci. 2003 Jun;994:49-57
12851297
J Clin Endocrinol Metab. 2003 Sep;88(9):4258-67
12970296
Diabetes. 2004 Oct;53(10):2696-9
15448103
J Biol Chem. 2003 May 2;278(18):15935-40
12594226
J Med Chem. 2008 Sep 25;51(18):5585-93
18800761
Endocrinology. 1999 Mar;140(3):1408-15
10067869
Biochemistry. 2005 Aug 30;44(34):11329-41
16114870
Nature. 1961 Jan 21;189:176-9
13761067
J Clin Endocrinol Metab. 2002 Oct;87(10):4442-6
12364415
FASEB J. 2009 Sep;23(9):3059-69
19417090
N Engl J Med. 2003 Mar 20;348(12):1096-103
12646666
J Med Chem. 2002 Oct 10;45(21):4589-93
12361385
Int J Obes Relat Metab Disord. 2002 May;26(5):647-51
12032748
Science. 2007 Nov 23;318(5854):1266-73
17962519
Mol Endocrinol. 1999 Jan;13(1):148-55
9892020
Biochemistry. 2006 Jun 13;45(23):7277-88
16752916
Clin Chem. 2005 Aug;51(8):1358-64
15951321
Biochem Biophys Res Commun. 1994 May 16;200(3):1214-20
8185570
Genes Dev. 1993 Mar;7(3):454-67
8449404
Endocrinology. 2003 Oct;144(10):4544-51
12959994
Mol Endocrinol. 2001 Jan;15(1):164-71
11145747
Diabetes. 2002 Jan;51(1):243-6
11756348
Br J Pharmacol Chemother. 1947 Sep;2(3):189-206
20258355
Endocr Rev. 1980 Winter;1(1):1-27
6262069
J Clin Invest. 2000 Jul;106(2):253-62
10903341
J Clin Endocrinol Metab. 2006 May;91(5):1761-9
16492696
Nat Med. 2002 Jul;8(7):643-4
12091883
Trends Pharmacol Sci. 1993 Aug;14(8):303-7
8249148
Anal Biochem. 1995 Apr 10;226(2):349-54
7793637
FEBS Lett. 1992 Sep 14;309(3):417-20
1516719
J Clin Endocrinol Metab. 2005 Jan;90(1):219-24
15486053
Chem Biol Drug Des. 2006 Mar;67(3):215-29
16611215
J Biol Chem. 1993 Jul 15;268(20):15174-9
8392067
J Am Chem Soc. 2002 Sep 18;124(37):11046-55
12224952
Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8856-60
8415620
Hum Mol Genet. 2003 Mar 1;12(5):561-74
12588803
Diabetes. 2003 Dec;52(12):2984-8
14633860
J Urol. 1998 Aug;160(2):389-93
9679884
J Biol Chem. 1997 Sep 12;272(37):23000-10
9287296
Nature. 2001 May 24;411(6836):480-4
11373681
J Med Chem. 2002 Jun 20;45(13):2801-10
12061882
J Biol Chem. 1999 Dec 10;274(50):35816-22
10585465
J Med Chem. 2002 Dec 19;45(26):5736-44
12477357
J Biol Chem. 1993 Apr 15;268(11):8246-50
8463333
J Endocrinol. 2002 Mar;172(3):411-21
11874690
N Engl J Med. 2009 Jan 1;360(1):44-52
19092146
J Med Chem. 2004 Apr 22;47(9):2194-207
15084118
Biochemistry. 2001 Dec 25;40(51):15520-7
11747427
J Med Chem. 2002 Jul 4;45(14):3073-81
12086493